TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02442648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered for desensitization per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered for desensitization per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered for desensitization per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib will be administered for desensitization per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered for desensitization per study protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered for desensitization per study protocol.
Study: NCT02711566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physioassistant: Haptic training
Description: Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Physioassistant: Sensorimotor training
Description: Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
Study: NCT04078724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 5-HTP
Description: 5-HTP that have Good Manufacturing Practice certification will be used and participants will be suggested to be take the 5-HTP supplementation at bedtime.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Without 5-HTP
Description: Subject will not take 5-HTP
Study: NCT00568217

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Diclofenac, Paracetamol, Ibuprofen
Description: Immediately if temperature \> 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still \< 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature \< 38 degree Celsius
Study: NCT02508103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study: NCT05724238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Traditional Herbal Supplements (Kuan Sin Yin)
Description: Astragalus-based Kuan Sin Yin
Study: NCT05724238

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo starch powder with 10% Kuan Sin Yin
Study: NCT01898377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate, Mycophenolate mofetil
Study: NCT02508103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
Study: NCT02906579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-1973
Study: NCT03422575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoricoxib 120Mg Film-coated Tablet
Description: One tablet of the Test drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arcoxia® 120 mg Film-coated tablet (Frosst Iberica S.A., Spain for Merck Sharp & Dohme (Australia) Pty Limited, Australia, registered by PT. Schering-Plough Indonesia Tbk)
Description: One tablet of the Reference drug was given orally (swallowed with 200 mL of water, without chewing), after an overnight fast, and after fasting (pre-dose) blood-sampling.
Study: NCT05721547

Intervention type: OTHER
Intervention: Assessment
Description: Assessment

Intervention type: OTHER
Intervention: Assessment
Description: Assessment
Study: NCT04209569

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Impact and Positive Practice Circle (NIPP)
Description: GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition Impact and Positive Practice Circle (NIPP)
Description: GOAL's NIPP approach is a gendered, grass-roots SBC approach, tackling a package of underlying behavioral determinants of malnutrition, irrespective of the particular manifestation. The approach is multi-sectoral in nature. It also has a strong monitoring, evaluation and adaptive learning component by design. The intervention approach (based on GOAL's NIPP approach) involves the creation of community, male and female circles in each community with messaging and activities targeted towards the three groups in varying intensities. While the male and female circles meet 2-3 times per week for a maximum period of 12 weeks while the community circles will meet for approximately three hours at any one time over a period of 2-7 days. (See GOAL NIPP Implementation Guidelines)
Study: NCT00776906

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Advance® 18PTX® Balloon Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Advance® 18LP Balloon Catheter
Study: NCT04371120

Intervention type: DIAGNOSTIC_TEST
Intervention: BICS Q
Description: assess perceived self-efficacy (PSE) regarding a person's brain injury and proved responsive to treatment effects in the original BICS study.15-16 Specifically, it measures a person's perceptions about his or her ability to both understand the effects of brain injury, as well as, perceived capability of managing BI-related challenges. As the literature suggests, it is important to utilize a measure that would assess PSE specific to the person's challenge, rather than a general PSE scale.
Study: NCT01970254

Intervention type: OTHER
Intervention: Hepatitis B Screening
Description: Undergo 3 HBV screening tests (HbsAg, anti-HBc, and anti-HBs)

Intervention type: OTHER
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT00890578

Intervention type: PROCEDURE
Intervention: adhesive to suture
Description: surgical closure

Intervention type: PROCEDURE
Intervention: adhesive to suture
Description: surgical closure
Study: NCT02330094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.~Both groups will receive other standard of care pain medications.
Study: NCT03805542

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.5% Iodophors
Description: Before lithotripsy, 0.5% iodophor 40 ml(depending on the degree of hydronephrosis) was used to perfuse the calculous side pelvis under low pressure for 5 minutes.
Study: NCT00540943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be supplied as a single-use 50 milliliter vial containing 100 micrograms of cetuximab as a sterile, preservative-free, injectable liquid at a concentration of 2 milligram per milliliter in phosphate.~buffered saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan hydrochloride trihydrate is an antineoplastic agent of the topoisomerase I inhibitor class.
Study: NCT02211547

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epic 10 Diode Laser by Biolase Inc.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
Study: NCT02563548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGPH20
Description: PEGPH20 will be administered as an intravenous (IV) infusion as per the dose schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as an IV infusion as per the dose schedule specified in the arm description.
Study: NCT00867698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AST-120
Description: AST-120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-120
Description: AST-120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AST-120
Description: AST-120
Study: NCT03057847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Velpatasvir
Description: Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
Study: NCT01114347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cranberry type A pro anthocyandines
Description: One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
Study: NCT02879383

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DMR Procedure
Description: The DMR procedure consists of hydrothermal ablation of the duodenum using the Revita System

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The sham procedure consists of placing the Revita Catheter into the stomach for 30 minutes and then removing it from the patient.
Study: NCT00980642

Intervention type: DEVICE
Group type: OTHER
Intervention: Draeger double-sensor
Description: The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.

Intervention type: DEVICE
Group type: OTHER
Intervention: Draeger double-sensor
Description: The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.

Intervention type: DEVICE
Group type: OTHER
Intervention: Esophageal stethoscope temperature sensor
Description: Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.

Intervention type: DEVICE
Group type: OTHER
Intervention: Foley catheter temperature sensor
Description: Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
Study: NCT04392492

Intervention type: DEVICE
Intervention: MANTA vascular closure device
Description: Femoral access site closure using the MANTA closure device
Study: NCT02526966

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sample
Description: dosage of anti-hinge region antibodies
Study: NCT04211090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Camrelizumab with pemetrexed / carboplatin in patients with brain metastases of driven gene-negative, non-squamous non-small cell lung cancer, Participants receive a 3-week cycle (Q3W) treatment，Treatment continued until disease progression or unacceptable toxicity or death or, for the immunotherapy regimens
Study: NCT04905576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation training
Description: Muscle relaxation training
Study: NCT03681899

Intervention type: OTHER
Intervention: Questionnaires
Description: * Socio-demographic data (age, sex, place of residence, and family status, last occupation, existence or not of a primary caregiver (family and / or professional));~* Medical and surgical history (Charlson Comorbidity Scale);~* Assessment of oral/dental condition~* Record of drug treatments (number of oral medications per day, therapeutic class, number of daily intakes);~* Oral treatments intake modalities (galenic breakdown of one or more drugs, usual or occasional, modalities of rupture, person responsible for the drugs, mixing with food / drink);~* Autonomy evaluation (Lawton and Katz scales);~* Mobility assessment (anamnestic evaluation);~* Evaluation of Thyme (GDS 4 items);~* Psycho-behavioral disorders,~* Assessment of swallowing (presence of a diagnosis of dysphagia or suspicion based on anamnestic data).
Study: NCT01347593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftizoxime
Description: ceftizoxime (cefizox) injection either after clamping the cord
Study: NCT00997347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone and misoprostol
Description: 200 mg oral mifepristone~800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone
Study: NCT04905576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic touch
Description: Healing Touch (HT) therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire administration

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire administration
Study: NCT02816320

Intervention type: OTHER
Intervention: Hospitalization
Description: Patients who were hospitalized in acute care
Study: NCT01314027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin
Description: Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.~Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant chemotherapy with gemcitabine
Description: Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
Study: NCT04905576

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancillary studies
Description: Subjects in all groups will give 4 blood samples during the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ancillary studies
Description: Subjects in all groups will give 4 blood samples during the study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ancillary studies
Description: Subjects in all groups will give 4 blood samples during the study
Study: NCT03504722

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RESCUE
Description: RESCUE is designed to adapt to individualized needs based on each veteran's performance. The volunteer training consists of weekly sessions lasting 90 minutes each and occurring at area SPCA facilities. The logistics of the training sessions will be facilitated by study staff, with SPCA animal behaviorists and professionals conducting the training program identical to the program that they use for their general volunteer training. During volunteer sessions, the veteran learns behavioral techniques for training non-aggressive dogs through didactic instruction followed by demonstration and supervised practice. The animal socialization component of the RESCUE volunteer sessions are comprised of the SPCAs current training program, which is designed developmentally such that early training focuses on general topics (safety, basic handling skills) and later training builds on previously learned skills through successive approximation within each individual's zone of proximal development.
Study: NCT02198508

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFX(Deferasirox)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFX(Deferasirox)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DFP(Deferiprone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP(Deferiprone)
Study: NCT03558685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss diet
Description: Nutritional recommendation consisted of moderate caloric restriction, set at 25% to 30% less than calories needed for resting metabolic rate. We applied a high protein Mediterranean diet with the following food group distribution: 30% as protein (\> 0.8 g/kg/d); 40% as carbohydrates with medium/low glycemic index; 30% as fat (≥10% monounsaturated fatty acid, ≤7% saturated fatty acid, no trans fats, and 1.6 g omega-3 for men and 1.1 g omega-3 for women). Diet was rich in olive oil, fish, chicken, nuts, white milk products, fruits, and vegetables but low in artificial sugars, commercial sweets, pastries, butter, margarine, and red meat. Dietary fiber content ≥25 g/day
Study: NCT01176123

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia
Description: Cognitive Behavioral Therapy for Insomnia
Study: NCT04034511

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medically-tailored meal delivery and medical nutrition therapy
Description: Home-delivered, medically-tailored meals for 3 months combined with monthly individual medical nutrition therapy sessions for 6 months